Sign In to Follow Application
View All Documents & Correspondence
View All Documents & Correspondence
Crystal Form Of Phenylamino Pyrimidine Derivatives
Abstract: ABSTRACT CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans. The compound of formula I, also known as AN-019, is: Formula-I Development code: AN- 019 CF,
Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence
Notices, Deadlines & Correspondence
Patent Information
Application #
Filing Date
04 March 2009
Publication Number
36/2016
Publication Type
INA
Invention Field
POLYMER TECHNOLOGY
Status
Email
Parent Application
Applicants
NATCO PHARMA LIMITED
NATCO HOUSE, ROAD NO.2, BANJARA HILLS,
HYDERABAD-500 033
Inventors
1. AMALA KISHAN KOMPELLA
NATCO PHARMA LIMITED, NATCO HOUSE,
ROAD NO.2, BANJARA HILLS, HYDERABAD-500 033
2. ADIBHATLA KALI SATYA BHUJANGA RAO
NATCO PHARMA LIMITED, NATCO HOUSE,
ROAD NO.2, BANJARA HILLS, HYDERABAD-500 033
3. SREENIVAS RACHAKONDA
NATCO PHARMA LIMITED, NATCO HOUSE,
ROAD NO.2, BANJARA HILLS, HYDERABAD-500 033
4. VENKAIAH CHOWDARY NANNAPANENI
NATCO PHARMA LIMITED, NATCO HOUSE,
ROAD NO.2, BANJARA HILLS, HYDERABAD-500 033
Specification
FORM 2 THE PATENTS ACT, 1970 (ACT 39 OF 1970)
COMPLETE SPECIFICATION (Section 10)
o*
CD
C=)
ai N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]- benzamide (formula I). The term "essentially pure" is understood in the context of the I»esent invention to mean that about 90 to 100 wt-%, about 95 to 100 wt-%, or, for example, about 99 to 100 wt-% of the crystals of formula I are present in the crystal form according to the invention, e.g., the FormJII crystal form.
In the context of stating that the Form-Ill crystal form of formula I exhibits an X-ray dif&action diagram essentially as in FIG. 3, the term "essentially" means that at least the majw lines of the diagram depicted in FIG. 3, i.e. those having a relative line intensity of more than 10%, especially more than 20%, as compared to the most intense line in the diagram, are present.
The crystal forms have the following properties:
The melting point in the DSC thermogram of the Form-Ill crystal form is 246.7®C. The melting point in the DSC thermogram of the Form-I crystal form is 234°C and Fonn-II crystal form is 240.47°C, 249.2°C (peak).
The X-ray diffraction diagrams also show other marked differences. In an embodiment, the essentially pure Form-Ill crystal form of the compoxmd of formula I shows the X-ray diffraction diagram indicated in FIG. 3.
In an embodiment, the invention relates to the Form-Ill crystal form of the compound of formula I which is characterised by the presence of crystals displaying the form shown m FIG. 9, for example, the Form-Ill crystal form in essentially pure form.
In an embodiment, the Form-Ill crystal form of the compound of formula I has a melting point of higher than 240 e.g., between 245 and 250
The (for example, essentially pure) Form-Ill crystal form is obtainable by the following method: Treating another crystal form, e.g., the Form-I or Form-II crystal form, of the cund of formula I, with a suitable polar solvent, e.g., N,N-di-lower alkyl-lower alkaaecarboxamide, such as N,N-dimethylformamide or N,N-dimethylacetamide, or, e.g., an alii^utic carboxylic acid such as acetic acid, or a mixtine of the above with a ketone, such as acetone, or a hydrophobic hydrocarbon, e.g., toluene or hexane, or a mixture thereof, at a suitable temperature.
In an embodiment, the compound of formula I is treated with a mixture of dimethyl formamide and acetone followed by treatment in acetone. In an embodiment, the compound of formula I is treated with a mixture of dunethyl formamide and hexane followed by treatment in hexane. In an embodiment, the compound of formula I is treated with a mixture of dimethyl formamide and toluene followed by treatment in toluene. In an embodiment, the compound of formula I is treated one or more times with acetic acid. In this context, treating or treatment refers to heating, cooling, refluxing, washing, suspendmg, or the like in the solvent or mixture of solvents. These embodiments each yield the Form-Ill crystal form of the compound of formula I.
In certain embodiments, the present method of producing the Form-IH crystal form of does not include treating another crystal form of the compound of formula I with chloroform, methanol, dichloromethane, ether (e.g., diethyl ether), water, ethyl acetate, or mixture thereof. In certain embodiments, the Form-Ill crystal form was not produced by treating another crystal form of the compound of formula I with chloroform, methanol, dichloromethane, ether (e.g., diethyl ether), water, ethyl acetate, or mixture thereof
Form-Ill crystal form of the compound of formula I as well as other forms possess useful pharmacological properties and may, for example, be used as anti-tumour agents.
The present invention also includes a method of preparing compound of formula I. This method can include:
providing a compound of formula VI, 3,5-bis trifluoro methyl benzoyl chloride; or I»epanng this compound by known methods;
condensing 4-methyl-3-nitro-aniline with the compound of formula (IV) at about 0 to about -10 ®C in chlorohydrocaiton solvent with addition of a basic compoimd to obtain a compound of formula III, ((3,5-bis trifluoromethyl)-N-(4-methyl-3-nitrophenyl»- benzamide;
reducing the compound of formula (HI) with stannous chloride/conc. HCl at reflux temperature for about 0.5 to about 1 hour to obtain a compound of formula IV, (3,5-bis trifluotomethyl)-N-(3-amino-4-methylphenyl)-)-benzamide;
condensmg the compound of formula IV with aqueous cyanamide at reflux temperature in n-butanol solvent to obtain a compound of formula V, (3,5-bis- trifluoromethyl)-N-(3-g;uanidino - 4-methylphenyl>benz^de;
condensing the compound of formula (V) with 3-dimethylamino-l-pyridin-3-yl- propenone in presence of base at reflux temperature to obtain the compound of formula (I). In an embodiment, the method is accomplished as described in Example 10.
The disclosures of U.S. Patent Application No. 11/714,565, filed March 5, 2007 (U.S. Publication No. US 2007/0232633, published on October 4, 2007) and of PCT Application No. PCT/IN 2005/000243, filed July 19, 2005 (PCT Publication No. W02006/027795, published on March 16,2006) are incorporated by reference herein in their entirety.
Embodiments of the present invention are described in the examples given below, which are provided to illustrate the invention only and therefore they should not be construed to limit the scope of the invention.
Examples
General Note
The principal compound of this invention of formula I (Indicated by development code AN- 019) is found to exhibit useful anti-tumor activity superior to some of the existing approved dn^ of this class. This compound is found to exhibit in three distinct polymorphic forms I, II and III as discussed above. Although all the forms exhibit valuable pharmacological properties and may be used as anti-tumor agents Form III was chosen for the biological activi^ evaluation based on its thermodynamic stability. The development code AN-024 refers to another compound of the same class described elsewhere by the inventors. The bio- efBcacy and activity of the compounds of this invention have been compared with the approved drugs like Imatinib mesylate and Dasatinib to serve as positive controls in this study. 'Imatinib mesylate' has been abbreviated and referred to as 'Imatinib' in this study.
Example 1 - Establishment of Anti-CML Activity of AN-019 in Nude Mice Implanted
With k562 cells figures lOA and lOB)
To determine anti-CML activity of compounds of this invention K562 cells were obtained from ATCC and nude mice were implanted with these cells. As control, Imatinib was used at the same concentration per kg body weight for comparison. Drug treatment was initiated IS days post implantation and for 48 days with daily ip injections of lOmg/kg. Blood was dmwn from the tail vein every 6*** day, percent K562 cells determined and percent leukemia growth index (LGI) calculated.
AN019-treated mice showed a steady decline in LGI after initiation of drug treatment. LGI for Imatinib-treated mice also showed a decline but significantly lagged AN019 treated mice. Forty-eight days after continuous ip injections, AN019-treated mice were comparable to normal control mice, and Imatinib-treated mice showed an LGI of 20±5 when compared to controls. Spleen immunohistochemistry for Crk protein reveled localiTation of K562 cells in the spleen in control mice. AN019-treated mice showed basal levels of Crk expression, vsiwreas Imatinib treated mice showed few colonies with low to imdetectable expression levels of Crk.
Methods
K562 implantation
Nude mice (nu/nu) were implanted with K562 cells (1x10^) via tail vein. Four mice were used per group and divided into 4 groups. Three groups were implanted with K562 cells and one group was used as normal controls. Group 2 was inoculated with K562 cells and served as untreated positive controls. Two other groups implanted with K562 cells were treated with either Imatinib or ANO19.
IP injcctioii of AN019 and Imatinib
K562 implanted mice were treated with either Imatinib or AN019 (lOmg/Kg body wt) via intr^)eritoneal injections. Stock solutions of Imatinib and AN019 were made at a coiK»ntratiott of 100^g/^l in DMSO. Mice were injected via an intraperitoneal route at the above-mentioned dosage. Average weight of nude mice was determined to be 30±3g, and the dosage per mouse was calculated to be 300t30ng/mouse. Three micro liters of the stock solutions was diluted to 100^1 with sterile water just prior to ip injections. Ip injections were carried out daily from day 15 post implantation to day 48 with a total of 33 injections.
Determination of leukemia growth index (LGI)
Leukoma growth index was determined using the formula LGI (%) - (Vc-Vt)A^c x 100%. Vc is mean blast cell number (K562) per ml of blood in control animals at a certain time of measurement, and Vt is mean blast cell number per ml of blood in test animals at a certain time of measurement. Blood was drawn from the mice (treated and untreated) on the sixth day post-K562 cell implantation and followed by an every six-day interval for 48 days. Blood was drawn -via the tm\ vein. Quantitative analysis of LGI was graphically represented.
Immunocytochemistiy
Control mice were sacrificed on day 42 when secondary leukemia symptoms were observed, such as abdominal swelling and lack of circulation in the peripherals causing loss of digits with red spots under the skin surface. Spleen and any secondary tumors were harvested, fixed in formaldehyde and paraffin embedded as per standard protocols. Paraffin section were obtained and processed for immunocytochemistry. The rehydrated sections were treated with 0.3% H2O2 to inactivate any native peroxidases prior to immuno-probing. The sections were blocked with filter sterilized (022\im) 1% BSA-PBS at room temperature for Ih. Following blocking, the sections were immuno-probed with a human specific anti-Crk monoclonal primary antibody raised in rabbit against a synthetic peptide corresponding to residues in the SH2 domain, near the N-term of human CrkL protein (Abeam, Cambridge, MA, USA) in 1%BSA-PBS overnight. Secondary antibody (anti-rabbit) conjugated to HRP was used to detect the presence of primary antibody. The sections were briefly rinsed three times in PBS solution after immuno-probing with secondary antibody, and DAB HRP substrate was added per manufacture's instructions (Sigma St Louis MO USA). The reaction was allowed to proceed until sharp contrast betweoi positive and negative controls was observed. For negative controls primary antibody were eliminated. Leukemic mice spleen served as positive controls.
RwBlte
Intr^)eritoneal injections of AN019 caused regression of leukemia in nude mice. Blood smears taken every sixth day post-implantation indicated an increase in LGI in controls wh^ compared to untreated mice. Tail vein drawn blood smears revealed an increase in LGI in controls and a progressive decrease in LGI in Imatinib-and AN019-treated mice (Fig. lOA). From the fifteenth day post-implantation, mice were given intr£q)eritoneaI injections of AN019 or Imatinib at a dosage of lOmg/kg body weight. Imatinib-treated mice lagged AN019-treated mice at every data point. On day 48 LGI of Imatinib-treated mice was determined to be 20±5, whereas LGI of AN019-treated mice was found to be 10±2 with an almost normal cell count (Fig. lOB).
RTamplft 1 - AN019 Injections of Nude Mice Implanted With KS62 Cells Did Not Show Spleenic Enlargement and No Crk Expression (Figure-11)
NikIc mice implanted with K562 ceils were treated with Imatinib or AN019 via ip injections. Mice were sacrificed after a decrease in LGI was observed and spleen harvested. Spleenic enlargement was observed by gross observation and it was determined that control mice diowed enlarged spleen indicative of K562 cellular localization. AN019-treated cells did not show any spleenic enlargement whereas Imatinib-treated mice showed slight spleenic enlargement (Fig 11), Parafifin sections of spleen unmuno-probed for the presence of Crk protein showed strong localiz^on of Crk expression accompanied with increased cellular density indicative of K562 localization in control mice. Mice treated with AN019 showed only basal level expression of Crk expression comparable to negative control. Mice treated wifli Imatinib indicated localized expression regions of Crk expression, indicative of K562 cells in the spleen. Control mice also developed random subcutaneous tumon showing Crk expressdon, indicative of the presence of K562 cells.
From these results it is evident that AN019 treatment caused the regression of LGI in nude mice. Imatinib-treated mice also showed significant reduction in LGI but lagged AN019- treated mice. Both AN019-and Imatinib-treated mice showed no abnormal physiological, I^miotypic or behavioral abnormality. Control mice showed the presence of random subcutaneous tumors with loss of digits accompanied with reddish spots under the skin and a sligfat enlargement of the abdomen. From these results, it is evident that AN019 provides a promising therapeutic drug for the treatment of leukemia.
Example 3 - In Vivo Studies Using Bag Imatinib Resistant Murine CML Cell Lines
To determine the in vivo anti-leukemic activity of AN019 and AN024, nude mice were implanted intraperitoneally with Baf3 murine leukemia cells (Wt, T315I, M351T and E225K), and 15 days after implantation the mice were treated with Imatinib (lOmg/kg), AN019 (20mg/kg) and AN024 (20mg/kg) by oral gavage or ip injections. Blood smears were obtained via the tail vein or via the femoral vein every 6th day and blast cells counted and graphically represented.
Blood smears of Ba£3Wt implanted mice treated with Imatinib (lOmg/kg), AN019 (20mg/kg) or AN024 (20mg/kg) were similar to normal controls after 42 days.
Blood smears of Baf3T315I implanted mice treated with Imatinib (lOmg/kg), AN019 (20mg/kg) or AN024 (20mg/kg) showed a significant decrease in blast cell count in AN024 and ANOl 9 treated mice. Mice treated with oral dosage of Imatinib did not show a decrease in blast cell count and were similar to untreated controls and Baf3M351T implanted mice.
Mice implanted with Baf3E255K also behaved similarly to Baf3M351T and Baf3T315I implanted mice.
Nude mice were implanted with Baf3 mutant cells Wt, E255K, T315I, and M351T were treated with Imatinib, ANOl9 and AN024 (orally and ip). Briefly, mice were treated with Imatimb (lOmg/kg), ANOl9 (20mg/kg) and AN024 (20mg/kg) by oral gavage or ip injections 15 days post-implantation. Abdominal swelling and decrease in activity was monitored daily, blood smear taken via the tail vein or the femoral vein every day and H&E stained as per standard protocols. 42 days after implantation, mice were sacrificed and spleens harvested. Spleenic enlargement was determined and correlated with blood smear blast cell count.
Results
Mierwcopic determination of blast cell count
Blood fix)m tail vein or the femoral vein was taken every 6th day from Baf3 cell implanted mice until day 42. On the 15th day post-unplantation, the mice were given treatments with Imatinib, ANOl9 and AN024 (orally and ip) as described earlier. It was obiserved that in BaGWt implanted mice, progressive decrease in blast cell count was observed in all treatment conditions. Baf3M351T, T315I and E225K did not respond well to Imatinib treatments. Oral administratioil of Imatinib had no significant effect in Baf3M351T, T315I and E225K implanted mice. Overall intraperitoneal treatments AN024 and ANOl 9 were significantly better at decreasing blast cell count in all Baf3 implanted mice.
AN019 treatment in BafiWt implanted mice induced a complete regression of leukemic blast cells and was comparable to untreated controls. Intraperitoneal treatments were superior to oral treatments. AN019 treatment in BaG M351T, T315I and E225K implanted mice showed a significant decrease in blast cell count and was comparable to 12th day post- implant in ip-treated mice at day 42; ip-treated mice showed greater regression of blast cells than oral treated mice. AN024 treatment in Ba£3 M35IT, T3151 and E225K implanted mice showed a significant decrease in blast cell count and was superior to AN019 treatment at day 42; ip-treated mice showed greater regression of blast cells than orally treated mice.
EiMttDle 4 - Response of nude mice implanted with k562 normal/luc human leukemic cells with low dose of AN024. AN019 and Imatinib fFignres 12 & 13) Nude mice (nu/nu) were implanted with K562 cells (1x106) normal/luc via tdl vein. Five mice were used per group and divided into 24 groups + 2 control. All groups were implanted with K562 normal/luc cells. Of the 24 groups, 12 were used for luciferase studies whereas Hw other 12 were used for blood smear count studies.
Oral administration of AN019. AN024 and Imatinib
Drags were administered by oral gavage (2% gum acacia and 2% SLS in an aqueous suspension).
Rcsntts
Oral administration of AN019 (1, 5,10 and 20mg/kg) in nude mice implanted with K562 luc human leukemia cells resulted in leukemia regression at higher concentrations. AN019 concentration at Img/kg did not induce a decrease in luciferase expression, whereas 5mg/kg caused fixation of leukemia cells at constant expression levels, and 10 and 20 mgAcg concentrations caused a decrease in luciferase expression (Figure 12). Oral administration of Imatinib (1,5,10 and 20mg/kg) in nude mice implanted with K562 luc human leukemia cells resulted in leukemia regression at higher concentrations. Imatinib administration at Img/kg concentration did not induce a decrease in luciferase expression, whereas lOmg/kg and 20mg/kg did show a retardation of luciferase expression (Figure 13).
The study shows the superiority of AN-019 over Imatinib in leukemic regression, particularly after 24 days of treatment.
Example 5 - Determinatioa of Pnig Effectivenessfl)..) and Drug Temporal Penetration Determination of drug effectiveness (Dj) Drug effectiveness was determined using the equation, De=
xlOO
c-ms&i
Where:
Saiive = total number of mice alive per concentration at the end of experiment times photon count. Slue = total number of mice alive showing luciferase expression per concentration at end of experiment and c represents control untreated animals times photon count and Z ^^
reiaeasents the initial number of animals in control at start of experiment times photon count The results were represented graphically as percent drug effectiveness (Table 7).
Results
Table 7 shows the drug effectiveness at various concentrations of Imatinib, AN019 and AN024 as determined from the in vivo studies. From Table 7 it is evident that AN019 behaved in a dose dependent maimer, whereas Imatinib and AN024 do not, and were effective at low concentrations.
Table 7
Drug 5mg/kg lOmg/kg 20mg/kg 40mg/kg
Imatinib De 10.00 32.00 13.33 8.00
AN019 De 25.82 78.20 83.40 85.20
AN024 De 30.00 85.00 87.00 90.00
Determination of drug temporal penetrance (Tp)
The temporal penetrance was calculated applying the following equation, Tp=.
rr
nj
< ^ J 9
v»/
Where:
P=photon counts at day 'a', day '/er', or day 'b' where 'a' is the day when drug treatment was stopped and 'ter' is the day when the experiment was terminated and 'b' is the day where P is minimum after day a but before day 'ter'. /j=number of animals alive when P was measured.
The larger the value indicates greater effectiveness of the drug after stopping drug treatment, i.e. the penetrance of the drug over time.
Rcsidts
To determine the temporal penetrance of AN019, AN024 and Imatinib, nude mice were impl^ted with K5621uc cells. The animals were imaged at 6 day intervals post transplantation. Drug treatment (AN019 20mg/kg, AN024 20mg/kg and Imatinib lOmg/kg) was initiated 15 days post implantation by daily ip injections. Drug treatment was stopped on day 35 and animals were imaged till day 45, and calculated as described in methods.
By aH)lying the equation for ten^wral penetrance, Tp values were determined as: AN019=2.0 AN024=2.4 Ifflatinib=0.8
These values of Tp indicate that AN024 had activity over untreated controls and fared better than AN019 for activity over time after withdrawal of drug treatment.
Example 6 - Effect of Dasatinib on BaO Implanted Nude Mice When Compared to AN024. AN019 and Imatinib rFieures 14A. 14B. and 140
Example 3 demonstrated the effectiveness of AN024 and AN019 in the treatment of leukemia when compared to Imatinib by using Baf3 (wt, T315I, M351T and E255K) mutant
cell lines. Here, we have used Dasatmib as a control drug to detennine the response of Baf3 mutant cells to treatment when compared to AN019, AN024 and Imatinib.
Method
The experimental layout is given in the tabular form as follows:
Tm^tt^t 4 cell Utie inaiitetiBd m T315I M351T mm
Centrcyls
j^viouBsly
oiial $ 5 5 J
m 5. S f .1 /
Nude mice were intraperitoneally implanted with Baf3 mutant cells (wt, T315I, M351T or E255K). 15 days following implaintation, the mice were treated either orally or intrq)eritoneally with lOmg/kg Dasatinib for 27 days. Blood was drawn fiom the femoral vein or tail vein every 6th day and blast cell count determined and graphically represented.
Results
On the day, blood smears of nude mice implanted with Ba£3 mutant cells (wt, T315I, M351T or E255K) showed normal blast cell count, and blast cell count progressively increased as observed on day 12. Dasatinib treatment was started on day 15 post implantation. Dasatinib treatmraits fared no better than Imatinib. On day 42, the termination of tl» experiment, mice implanted with wt cells showed significant response to Dasatinib, indicating that ip treatments were superior to oral. Mice implanted with T315I and M351T cells behaved similar to controls with no significant decrease in blast cell count. Mice implanted with E255K fared only a little better than T315I implanted cells in response to Dasatinib treatment. Overall Dastinib treatment only caused retardation in leukemic progress with no significant curative effect. Blast cell count was significantly lower in the group treated with AN019. These results are illustrated in Figures 14A, 14B, and 14C.
Example 7 - In vitro Studies on Glioma and Breast Cell Lines (Figures 15-18) Material and Methods
To determine the effect of AN019, AN024 and Temozolomide with or without radiation on glioma and breast cancer cells, cells were treated at the specified doses and determined invasion, angiogenesis and changes in certain signaling moleciiles.
Matrigel invasion assay
The in vitro invasiveness of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of compounds were assessed using a modified Boyden chamber assay. Cells were treated with these compounds for 48 h. 1x10® cells were suspended in 600^1 of serum-fi«e medium supplemented with 0.2% BSA and placed in the upper compartment of the transwell chambers (Coming Costar Fischer Scientific Cat #07-200-158, Pittsburgh PA) coated with Matrigel (0.7 mg/ml). The lower compartment of the chamber was filled with 200 of serum medium and the cells were allowed to migrate for 24 h. After incubation, the cells were fixed and stained with Hema-3 and quantified as previously described (Mohanam et al. 1993). The migrated cells were imaged microscopically to determine the reduction in invasiveness induced by the compounds of this invention.
Angiogenic assay
The in vitro angiogenesis of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of compounds were determined as follows, cells (2xl04/well) were seeded in 8-well chamber slides and were treated vdth various concentrations of test compounds. After a 24 h incubation period, the conditioned media was removed and added to a 4x104 human dermal endothelial cell (monolayer in 8- well chamber slides) and the human dermal endothelial cells were allowed to grow for 72 h. Cells were then fixed in 3.7% formaldehyde and stained with H&E and photographed.
Western blot analysis
Western blot analysis of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of compounds were assessed as per standard protocols. Cells were treated with AN019, AN024 or Temozolomide at the specified concentrations. 24h after treatment, cells were collected and cell lysates extracted. Equal quantities of proteins were fractionated by SDS-PAGE. The fractionated proteins were blotted on to nylon membranes and immunoprobed for AKT, ERK and Pi3k. Breast cancer cell protein isolates were additionally immunoprobed for EGFR, ErbBl, ErbB2 and ErbB3.
Rwulte
Mutrigel invasion assay
The in vitro invasiveness of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast canco- cells in the presence of specified concentrations of compounds were assessed usii^ a modified Boyden chamber assay. Cells were treated with these compounds for 48 h. Table 2 shows the results fi-om the studies of \n vitro matrigel invasion assay of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of compounds, with and without radiation.
Change in the invasiveness of various cell lines is given in Table 8. From the invasion assay it is evident that AN019 and AN024 were the most effective at inhibiting invasion in a nuyority of the cells, both with and without radiation.
Table 8
Cell line Drug -Radiation % Invasion +Radiation % Invasion ± Change in invasion after radiation
ZR-71 Temozolomide 70% 65% -5%
AN024 48% 45% -3%
AN019 33%, 19% -14%
MDA-MB-231 Temozolomide 62% 49% -13%
AN024 43% 47% +4%
AN019 45% 15% -30%
4910 Temozolomide 95% 73% -22%
AN024 56% 39% -17%
AN019 42% 15% -27%
5310 Temozolomide 50% 63% +13%
AN024 27% 32% +5%
AN019 5% 6% +1%
U87 Temozolomide 90% 93% +3%
AN024 53% 29% -24%
AN019 18% 18% 0%
Figures 15 and 16 illustrate the results of the in vitro matrigel invasion assay of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of q)ecified concentrations of AN-019, with and without radiation.
Angiogenic assay
From the angiogenesis assay experiments it is observed that AN019 was the most effective at inhibiting angiogenesis.
Temozolomide treatment caused complete inhibition of angiogenesis in ZR-71 cells, whereas in MDA-MB-231 cells only a slight inhibition was observed in control condition with an increase in inhibition after radiation. Glioma xenograft cells 4910 showed significant inhibition of angiogenesis both with and without radiation. In the case of 5310 cells inhibition of angiogenesis was seen in control conditions, whereas angiogenesis was I»omoted after radiation treatment. U87 glioma cells showed similar inhibition patterns both with and without radiation.
AN024 treatment caused complete inhibition of angiogenesis in ZR-71 cells, whereas in MDA-MB-231 cells only a slight inhibition was observed in control and radiation treatments. Glioma xenograft cells 4910 showed significant iiAibition of angiogenesis both with and without radiation. In the case of 5310 cells inhibition of angiogenesis was seen in control conditions, whereas angiogenesis further inhibited after radiation treatment. U87 glioma cells showed significant retardation in angiogenesis with an increase in inhibition after radiation.
AN0I9 treatment caiised complete inhibition of angiogenesis in ZR-71 cells, whereas in MDA-MB-231 cells a slight inhibition was observed in both control and radiation treatments. GlitMna xenograft cells 4910 showed inhibition of angiogenesis similar to MDA-MB-231 cells with an increase in angiogenic inhibition after radiation. In the case of 5310 cells inhibition of angiogenesis was greater in control conditions than after radiation treatment. U87 glioma cells showed s^lar significant retardation in angiogenesis both with and without radiation.
Figure 17 illustrates results obtained firom the in vitro angiogenic assay of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of AN-019, vwth and without radiation.
Wtetern blot analysis
Western blot analysis of 4910,5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of compounds of this invention revealed that U87 cells did not show significant change in AKT or PI3k levels both with and without radiation, whereas a slight decrease in ERK levels was observed in AN024 treated cells and decrease was enhanced after radiation. 4910 cells behaved similar to U87 cells with a decrease in AKT levels in after AN024 treatment and the decrease in AKT levels was enhanced after radiation. In case of 5310 cells no significant observable difference was seen in ERK expression whereas AN019 treatment caused a decrease in AKT expression levels. Levels of PI3k were almost undetectable in AN019 treated cells without radiation but reappeared after radiation treatment. In case of breast cancer cells MDA-MB-231 no significant change in AKT, ERK or PI3k was observed, whereas in case of ZR71 AN019 treatment caused a decrease in AKT levels, which was enhanced after radiation. AN024 treatment did not show any significant change under unirradiated conditions, whereas after radiation ANp24 treated cells showed a decrease in AKT expression. PI3k levels were absent in AN019 treatments both with and without radiation. AN024 treatment caused decrease in PI3k levels after radiation. Levels of pAKT did not change significantly in any of the treatments with or without radiation, whereas levels of pERK reduced significantly eiq)ecially in cell treated with AN019 both with and without radiation, AN024 also showed reduction on pERK levels but to a lesser extent than AN019. Temozolomide treatments both with and without radiation did not show any significant change in pAKT of perk levels.
Figure 18 illustrates the results of Western blot analysis of 4910, 5310 and U87 glioma cells and MDAMB231 and ZR71 breast cancer cells in the presence of specified concentrations of AN-024, with and without radiation.
Example 8 - Leukemic survival study (Figures 19-21)
K562 hiciferase expressing cells were implanted intraperitoneally into nude mice; the mice were scanned using the xenogeny IVIS image station after ip injections of luciferin does determine implantations. Drug treatment was started as in previous studies day 15 after implantation. The animals were given treatment till day 42, after which drug treatment was stopped and survival of the animals determined as per the animal care regulations. It observed that control animals developed leukemia and mortality had occurred on day 34 and 35, as per regulations we were advised to sacrifice the remaining 8 animals on day 35. Drug treatment was withdrawn on day 42 post implantation ^d survival of animals determined.
Animals treated with AN024 showed mortality on day 38, the dead animals on further inspection did not reveal spleenic enlargement and cause of death was determined to be other
than leukemia, blood smears could not be taken from the dead animal. Of the 10 animals used 8 animals showed no signed of leukemia on day 55.
Animals treated with AN019 did not show any mortality and 7 of the 10 animals showed complete absence of leukemic symptoms.
Animals treated with Imatinib showed reoccurrences, of leukemic symptoms after treatment withdrawal and showed mortality on day 55, 56, 57 and 58. The surviving animals did show presence of leukemic symptoms.
Figure 19 illustrates the amount of luciferase expression of K5621uc obtained from implanted mice after treatment with AN024, AN019 or unatinib.
Figure 20 illustrates the number of animals cured after treatment with AN024 or AN019 at day 58. Drug treatment was stopped at day 42, animals continued to show curative effect after treatment with AN024 and ANOl 9 after withdrawal of drug treatment.
Figure 21 illustrates blast cell count from blood smears taken from animals at the day indicated. Drug treatment was withdrawn on day 42. AN024 and ANOl9 showed effectiveness after withdrawal of drug treatment. Imatinib was found to be ineffective.
Example 8A - Stttdies on ED^ LD)-benzainide
A suspension of novel (3,5-bis trifluoromethyl)-N-(4-methyl-3-nitrophenyl)-benzamide (160 g, 0.41moles) and stannous chloride (460.8 g, 2.0 moles) in absolute ethanol (850 ml) was healed to reflux temperature for 40 min. The resulting suspension was then cooled to room temperature and quenched into 5 L of ice cold water. The reaction mixture pH was adjusted to 8.0 with 4.3 L of 5% sodium hydroxide solution and extracted with 2 x 2 L of ethyl acetate. The ethyl acetate layer was washed successively with water and brine and dried over sodium sulfate. The ethyl acetate was distilled completely and 500 ml of hexane was added to the residue and filtered. The filtered cake was dried at high vacuum at 60®C to give 96.0g of novel (3,5-bis trifluoromethyl)-N-(3-amino-4-methylphenyl)-)-benzamide (65%) as yellow crystals. (98.5% puritybyHPLC) MR-153-156°C
Step (HI): Preparation of (3,5-bis-trifluoromethyl)-N-(3-guanidino-4-methylphenyl)- bmzamide:
A suspension of (3,5-bis-trifluoromethyl)-N-(3-amino-4-methylphenyl)-benzamide (90 g, 0.20 mol) in n-butanol (500 ml) was treated sequentially with concentrated Nitric acid until the pH reaches 2.5 (15.9 g) and with a solution of cyanamide (15.7 g, 0.37 mol) in water (15 ml) over a period of 30 min. The resulting reaction mixture was stirred at reflux temper^ure for 6 hrs. The reaction mixture was then distilled oflf completely under vacuum and the residue was allowed to cool down to room temperature. A mixture of 180 ml of methanol and 180 ml of IPE was added to the reaction mass and stirred at room temperature for 1 hr. The product was filtered off with suction, washed with a mixture of methanol and IPE (3 X 50ml) and dried in vacuum at 60° C to give 72g of the nitrate salt of novel (3,5-bis- trifluoromethyl)-N-(3-guanidino - 4-methylphenyl)-benzamide of the formula 62% of theory (99.2% purity by HPLC), MR-285-287°C
Step (IV): Preparation of (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)phenyl]-ben2amide(I):
A suspension of (3,5-bis-Mfluoroniethyl)-N-(3-guamdino-4-methylphenyl)-benzamide nitrate (70 g, 0.15 mol) in n-butanol (470 ml) under an atmosphere of nitrogen was treated successively with sodium hydroxide flakes (7.0 g, 0.18 mol) and 3-dimethylamino-l-pyridin- 3-yl-propenone (28.0 g, 0.16mol). The resulting suspension was heated to reflux temperature for 2 hrs. The reaction mixtures became a homogeneous deep orange solution and dimethylamine was removed by the distillation of n-butanol. Reaction mass was cooled down to RT and a mixture of water and chloroform (300 ml + 300 ml) was added and chloroform layer was separated out. The chloroform layer was washed with water and distilled to a residual volume of 70 ml. Ethyl acetate (350 ml) was added to the reaction mass and filtered off with suction, the isolated solid was washed with ethyl acetate (2 x 50ml) and water (2 x 50 ml) and dried in vacuum at 60''C.
Yield: 48.0g of (3,5-bis trifluoTomethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)phenyl]-benzamide of the formula I.
The compound of formula-I obtained by Step-IV process was suspended in 480ml Chloroform and heated to 50-55°C. The reaction mass was cooled to room temperature and then cooled further to -5-0°C. The product was filtered and washed with Chloroform (250ml). The wet cake was dried for 6 hours at 60®C. The yield was 40gms. Melting range -230 -237X (DSC).
FIG. 1 of the drawings accompanying this specification shows the X-Ray Powder Dif&action (XRPD) pattern which substantially depicts a typically pure sample of form-I prepared as per the process disclosed in this Example The 29 values and intensities are tabulated m Table 1.
FIG. 4 shows tile DSC thermogram of form-I crystal modification prepared by the process described in this Example (run from 40.0 - 325®C 10.00°C/min; N2 80 ml/min).
FIG.7 shows crystals of Form-I crystal modification of compound of formula (I)
Example 11 - Preparation of Foim-II
(3,5-Bis trifluoiX)methyl>N-[4-methyl-3-(4-pyridin-3yl-pyriimdin-2ylan^
benzamide of formula I, was prepared as per the process of Example 4 in W02006/027795 (US 2007/0232633) as follows:
Alternative process for the Preparation of (3^-bis trifluoromethyl)-N-[4-methyl-3-(4- pyridin-3-yI-pyrimidin-2-ylamino)-phenyl] - benzamide
In the first instance, 3,5-bis trifluoro methyl benzoyl chloride which was used as one of the starting material was prepared as follows:
Thionyl chloride (2.04 kg. 17.2mol) was added over a period of 15 min to a solution of 3,5- bis trifluoro methyl benzoic acid (855.0 g, 3.3mol) and D.M.F.(9 ml) in chloroform (9 L) at KXMn temperature. The reaction mixture was heated to reflux temperature for 1 hour. The excess of thionyl chloride is removed by co-distillation with chloroform under reduced pressure at 40°C. After the end of the distillation, the resulting 3,5-bis trifluoro methyl benzoyl chloride was cooled down to room temperature and dissolved in 700 ml chloroform.
A solution of N-(5-amino-2-methylphenyl)-(3-pyridyl>2-pyrimidine amine (0.73kgs, 2.64mol) in chloroform (9L) was cooled to -5°C and triethyl amine (1.03 kg, 10.2mol) was added. 3,5-Bis trifluoro methyl benzoyl chloride in chloroform was added drop wise at -5° C ovCT a period of 60-75 min. The resulting suspension was stirred for 1 hr at -5° C. The suspension was filtered, washed with D.M. water and methanol vacuum to give 1.3 kg of wet crude title compound which on recrystallization from methanol yielded 0.82 Kgs (60%) of (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]- benzamide(I)
The compound of formula-I obtained by the above process was suspended in 5L methanol and heated to reflux temperature. The reaction mass was maintained at the same temperature for 30-40 minutes, cooled slowly to 40-45°C and held at this temperature for 60 minutes. The product was filtered and washed with 0.5L methanol at 40-45°C. The wet cake was dried for 6 hours at 60®C. Yield: 650gnis
FIG. 2 of the drawings accompanying this specification shows the X-Ray Powder Diffraction (XRPD) pattern which substantially depicts a typically pure sample of Form-II prepared as per the process disclosed in this Example The 29 values and intensities are tabulated in Table-2.
FIG. 5 shows the DSC thermogram of form-II crystal modification prepared by the process described in this Example (run from 30,0 - 350°C 10.00°C/min; N2 80 ml/min).
FIG. 8 shows crystals of Form-II crystal modification of compound of formula (I).
Example 12 - Preparation of Form-in
(3,5-Bis trifluorome%l)-N-[4-me%l-3<4-pyridin-3yl-pyrimidm-2ylamino)-phenyl]- benzamide of formula I, was prepared as per the process of Example 4 in W02006/027795 as mentioned in the above Example-11.
The compound of formula-I obtained by the above process was suspended in a mixture of 2.5L Dimethyl formamide and 4.1L acetone and heated to 50°C. The reaction mass was maintained at the same temperature for 30-40 minutes, then cooled slowly to 25-30®C and held at the same temperature for 60 minutes. The product slurry was fiirther cooled to -5®C and filtered and washed with 0.8L Acetone . The wet cake was suspended in 0.4L acetone and heated to reflux temperature. The cooled slurry was filtered and washed with 0.4L acetone. The wet cake was dried for 6 hours at 60®C. Yield: 500gms.
FIG. 3 of the drawings accompanying this specification shows the X-Ray Powder Dif&action (XRPD) pattern which substantially depicts a typically pure sample of form-III
prepared as per the process disclosed in this Example The 29 values and intensities are tabulated in Table 3.
FIG. 6 shows the DSC thermogram of form-III crystal modification prepared by the process described in this Example (run fi-om 40.0 - 325°C 10.00°C/min; N2 80 ml/min).
FIG. 9 shows crystals of Form-III crystal modification of compound of formula (I).
ExamDle-13 - Preparation of Form-ni
(3,5-Bis trifluorome%l)-N-[4-me%10-(4-pyridm-3yl-pyrimidin-2ylamino)-ph^ benzamide of formula I, was prepared as per the process of example-4 in W02006/027795 as mentioned in the above example-11.
The compound of formula-I obtained by the above process was suspended in a mixture of 2.5L dimethyl formamide and 4.1L Hexane and heated to 50°C. The reaction mass was maintained at the same temperature for 30-40 minutes, cooled slowly to 25-30°C and held at the same temperature for 12 hours. The product slurry was fiirther cooled to -5°C, filtered and washed with 0.8L Hexane. The wet cake was dried for 6 hours at 60°C. Yield: 400gms; DSC: 24«.2(peak).
Example 14 - Preparation of Form-ffl
(3,5-Bis M£luoromethyl)-N-[4-methyI-3-(4-pyridin-3yl-pyrimidin-2yIaniino)-phenyl]- benzamide of formula I, was prepared as per the process of Example 4 in W02006/027795 as mentioned in the above Example 11.
The compoimd of formula-I obtained by the above process was suspended in a mixture of 2.5L dimethyl formamide and 4.1L toluene and heated to 50®C. The reaction mass was maintained at the same temperature for 30-40 minutes, cooled slowly to 25-30°C and held at the same temperature for 12 hours. The slurry was cooled further to -5°C, filtered and washed with 0.8L Toluene . The wet cake was dried for 6 hours at 60®C. Yield: 450gms; DSC: 246.7(peak).
Example 15 - Preparation of Form-Ill
(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-ph^ benzamide of formula I, was prepared as per the process of example -4 in W02006/027795 as mentioned in the above example-11
The compoimd of formula-I obtained by the above process was suspended in a mixture of 2.5L Acetic acid and heated to 50°C. The reaction mass was maintained at the same temperature for 30-40 minutes, cooled slowly to 25-30°C and held at the same temperature for 96 hours. The product was filtered and washed with 0.4L chilled Acetic acid . The wet cake was dried for 6 hours at 60°C. Yield: 650gms; DSC : 246.3 (peak).
Example 16 - Preparation of Form-Ill
The Form-I prepared by Example-lO (40g)was suspended in a mixture of 120ml dimethyl formamide and 200ml acetone and heated to 50°C, The reaction mass was maintained at the same temperature for 30-40 minutes, cooled slowly to 25-30°C and held at the same temperature for 60 minutes. The slurry was cooled -5°C, filtered and washed with 40ml Acetone . The wet cake was suspended in 200ml acetone and heated to reflux temperature and maintained for 60 mmutes at reflux temperature. The slurry was cooled to 25®C, filtered and washed with 40ml acetone. The wet cake was dried for 6 hours at 60°G. Yield: 25gms; DSC: 247.0 (Peak).
Example 17 - Preparation of Form-Ill
The Fonn-II prepared by Example-11 (650g) was suspended in a mixture of 1.95L dimethyl fonnamide and 3.25L acetone and heated to 50°C. The reaction mass was maintained at the same temperature for 30-40 minutes. The reaction mass was cooled slowly to 25-30°C and maintained at the same temperature for 60 minutes. The product was filtered and washed with 0.7L Acetone. The wet cake was suspended in 3.5L acetone and heated to reflux temperature. The slurry was cooled to 25®C, filtered and washed with 0.7L acetone. The wet cake was dried for 6 hours at 60°C. Yield: 395gms; DSC: 246.5 (Peak).
As used herein, the term "about" refers tathe variation in an amount or range that is conventional for the field of organic chemistry, for example, the typical variation that occurs in temperatures or times as measured in real world situations in the organic chemistry laboratory, scale-up, or production facility, or in evaluating anti-proliferative agents. Any range or amount used in the description of the present invention that is modified by the term "about" is also a part of the invention if not modified by the term about. For example, recitation of "about 10 to about 20" also includes recitation of "10 to 20".
It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing "a compound" includes a mixture of two or more compounds. It shoidd also be noted that the term "or" is generally employed in its sense including "and/or" imless the content clearly dictates otherwise.
All publications and patent applications in this specification are indicative of the level of ordinary skill m the art to which this invention pertains.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
WECLAIM:
1. A Form-III crystal form of (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4- pyridin-3yl-pyrimidin-2ylainino)-phenyl]-benzainide (formula I).
2. The Form-UI crystal form of claim 1, wherein tiie Form-Ill crystal form has the XRPD characteristics:
Angle [2-Theta] d-value Angstrom Intensity %
5.909 14.94417 24.9
6.491 13.60517 66.4
8.267 10.68690 100.0
11.854 7.45967 58.2
13.181 6.71147 40.0
14.609 6.05866 50.0
15.960 5.54851 5.8
16.612 5.33224 9.5
18.826 4.70995 14.4
19.571 4.53226 52.1
21.302 4.16774 54.0
21.612 4.10861 37.7
22.160 4.00828 3.5
22.970 3.86869 23.8
23.278 3.81812 51.6
24.000 3.70491 8.7
25.112 3.54329 11.1
25.887 3.43895 3.1
26.500 3.36079 3.3
27.517 3.23887 3.4
29.476 3.02788 6.8
29.857 2.99011 8.6
30.474 2.93102 3.5
32.886 2.72133 3.2
33.559 2.66829 5.0
35.916 2.49836 3.8
39.645 2.27157 4.9
43.061 2.09893 2.6
43.748 2.06753 3.8
44.055 2.05383 3.9.
3. The Fonn-III crystal form of claim 1, wherein the crystal form has melting point at or above 240 °C.
4. The Form-Ill crystal form of claim 1, wherein the crystal form is essentially
pure.
5. A method of treating a subject in need of 'anti-proliferative therapy, tiie method comprising:
administering to the subject a Form-Ill crystal form of (3,5-bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I).
6. The method of claim 5, wherein the Form-Ill crystal form has the XRPD cluffacteristics:
Angle r2-Thetal d-value Angstrom Intensity %
5.909 14.94417 24.9
6.491 13.60517 66.4
8.267 10.68690 100.0
11.854 7.45967 58.2
13.181 6.71147 40.0
14.609 6.05866 50.0
15.960 5.54851 5.8
16.612 5.33224 9.5
18.826 4.70995 14.4
19.571 4.53226 52.1
21.302 4.16774 54.0
21.612 4.10861 37.7
22.160 4.00828 3.5
22.970 3.86869 23.8
23.278 3.81812 51.6
24.000 3.70491 8.7
25.112 3.54329 11.1
25.887 3.43895 3.1
26.500 3.36079 3.3
27.517 3.23887 3.4
29.476 3.02788 6.8
29.857 2.99011 8.6
30.474 2.93102 3.5
32.886 2.72133 3.2
Angle [2-Theta] d-value Angstrom Intensity %
33.559 2.66829 5.0
35.916 2.49836 3.8
39.645 2.27157 4.9
43.061 2.09893 2.6
43.748 2.06753 3.8
44.055 2.05383 3.9.
7. A pharmaceutical composition comprising a phannaceutically acceptable excipient and a Fonn-III crystal form of (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin- 3yI-pyrimidin-2ylamino)-phenyl]-benzaniide (formula I).
8. The pharmaceutical composition of claim 7, wherein the Form-III crystal form has the XRPD characteristics:
Angle [2-Theta] d-value Angstrom Intensity %
5.909 14.94417 24.9
6.491 13.60517 66.4
8.267 10.68690 100.0
11.854 7.45967 58.2
13.181 6.71147 40.0
14.609 6.05866 50.0
15.960 5.54851 5.8
16.612 5.33224 9.5
18.826 4.70995 14.4
19.571 4.53226 52.1
21.302 4.16774 54.0
21.612 4.10861 37.7
22.160 4.00828 3.5
22.970 3.86869 23.8
23.278 3.81812 51.6
24.000 3.70491 8.7
25.112 3.54329 11.1
25.887 3.43895 3.1
26.500 3.36079 3.3
27.517 3.23887 3.4
29.476 3.02788 6.8
29.857 2.99011 8.6
30.474 2.93102 3.5
32.886 2.72133 3.2
33.559 2.66829 5.0
35.916 2.49836 3.8
Angle [2-Thetal d-value Angstrom Intensity %
39.645 2.27157 4.9
43.061 2.09893 2.6
43.74§ 2.06753 3.8
44.055 2.05383 3.9.
9. Use of a Foim-III crystal form of (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4- pyridin-3yl-pyririiidin-2ylainiiio)-phenyl]-ben2amide (formula I), wherein the Form-Ill crystal form has the XRPD characteristics:
Angle [2-Theta] d-value Angstrom Intensity %
5.909 14.94417 24.9
6.491 13.60517 66.4
8.267 10.68690 100.0
11.854 7.45967 58.2
13.181 6.71147 40.0
14.609 6.05866 50.0
15.960 5.54851 5.8
16.612 5.33224 9.5
18.826 4.70995 14.4
19.571 4.53226 52.1
21.302 4.16774 54.0
21.612 4.10861 37.7
22.160 4.00828 3.5
22.970 3.86869 23.8
23.278 3.81812 51.6
24.000 3.70491 8.7
25.112 3.54329 11.1
25.887 3.43895 3.1
26.500 3.36079 3.3
27.517 3.23887 3.4
29.476 3.02788 6.8
29.857 2.99011 8.6
30.474 2.93102 3.5
32.886 2.72133 3.2
33.559 2.66829 5.0
35.916 2.49836 3.8
39.645 2.27157 4.9
43.061 2.09893 2.6
43.748 2.06753 3.8
44.055 2.05383 3.9
for producing an anti-proliferative medicament for treating a tumor disorder.
10. A process for preparing a Form-Ill crystal form of (3,5-bis trifluoromethyl)- N-{4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I)
the process comprising:
treating the compound of formula I in a Form-I or Form-II crystal form with acetic acid or a mixture of dimethyl formamide and acetone, hexane, or toluene; and,
subsequently treating the once treated compound with acetic acid, acetone, hexane, or toluene.
11. The process of claim 10, comprising:
treating the compound of formula I in a Form-I or Form-II crystal form with acetic acid; and,
subsequently treating the once treated compound with acetic acid.
12. The process of claim 10, comprising:
treating the compound of formula I in a Form-I or Fom^-II crystal form with a mixture of dimethyl formamide and acetone; and,
subsequently treating the once treated compound with acetone.
13. The process of claim 10, comprising:
treatii^ the compound of formula I in a Form-I or Form-II crystal form with a mixture of dimethyl formanaide and hexane; and,
subsequently treating the once treated compound with hexane.
14. The process of claim 10, comprising:
treating the compound of formula I in a Form-I or Form-II crystal form with a mixture of dimethyl formamide and toluene; and,
subsequently treating the once treated compound with toluene.
15. The process of claim 10, wherein the Form-Ill crystal form has the XRPD characteristics:
Angle [2-Thetal d-value Angstrom Intensity %
5.909 14.94417 24.9
6.491 13.60517 66.4
8.267 10.68690 100.0
11.854 7.45967 58.2
13.181 6.71147 40.0
14.609 6.05866 50.0
15.960 5.54851 5.8
16.612 5.33224 9.5
18.826 4.70995 14.4
19.571 4.53226 52.1
21.302 4.16774 . 54.0
21.612 4.10861 37.7
22.160 4.00828 3.5
22.970 3.86869 23.8
23.278 3.81812 51.6
24.000 3.70491 8.7
25.112 3.54329 11.1
25.887 3.43895 3.1
26.500 3.36079 3.3
27.517 3.23887 3.4
29.476 3.02788 6.8
29.857 2.99011 8.6
30.474 2.93102 3.5
32.886 2.72133 3.2
33.559 2.66829 5.0
35.916 2.49836 3.8
39.645 2.27157 4.9
43.061 2.09893 2.6
43.748 2.06753 3.8
44.055 2.05383 3.9
16. A Form-I crystal fonn of (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin- 3yl-pyrimidin-2ylainino)-phenyl]-benzainide (formiila I).
17. The Form-I crystal form of claim 16, wherein the Form-I crystal form has the XRPD characteristics:
Angle [2-Theta] d-value Angstrom Intensity %
6.793 13.00131 13.9
Angle [2-Theta] d-value Angstrom Intensity %
9.823 8.99680 3.9
11.106 7.96069 54.2
13.267 6.66829 48.5
16.386 5.40523 7.0
17.941 4.94015 11.3
18.997 4.66785 13.0
19.778 4.48530 50.5
21.894 4.05635 100.0
22.396 3.96650 20.5
23.469 3.78750 19.7
24.466 3.63545 32.4
24.939 3.56759 52:6
25.525 3.48695 14.6
26.968 3.30351 10.3
28.777 3.09991 22.0
30.545 2.92436 14.8
33.011 2.71129 11.0.
18. A Form-II crystal form of (3,5-bis trifluoromethyl)-N-[4-me1hyl-3-(4-pyridin- 3yl-pyrunidin-2ylainino)-phenyl]-benzamide (formula I).
19. The Fonn-II crystal form of claim 18, wherein the Form-II crystal form has the XRPD characteristics:
Angle [2-Thetal d-value Angstrom Intensity %
6.500 13.58651 12.2
10.816 8.17295 100.0
12.094 7.31197 3.4
12.988 6.81061 49.7
16.120 5.49381 6.0
17.669 5.01562 10.9
19.521 4.54367 41.7
21.675 4.09687 39.9
22.083 4.02198 17.1
23.230 3.82602 21.9
24.264 3.66523 17.8
24.639 3.61023 8.5
28.460 3.13371 4.8
29.328 3.04290 2.3
30.256 2.95165 4.1
32.746 2.73261 3.5
Angle [2-Thetal d-value Angstrom Intensity %
34.035 2.63201 3.1
35.590 2.52050 1.5
39.660 2.27072 1.9
42.123 2.14346 2.5
44.193 2.04777 1.7
20. A method of preparing compoimd of fonnula I:
CF,
Fonnula I
Development code: AN-019
the method comprising:
providing a compound of fonnula VI, 3,5-bis trifluoro methyl benzoyl chloride; condensing 4-methyl-3-nitro-aniline with the compoimd of formula (TV) at about 0 to about -10 °C in chlorohydrocarbon solvent with addition of a basic compound to obtain a compound of formula HI, ((3,5-bis trifluoromethyl)-N-(4-methyl-3-nitrophenyl)-)- benzamide;
reducing the compound of fonnula (III) with stannous chloride/conc. HCl at reflux temperature for about 0.5 to about 1 hour to obtain a compoimd of formula IV, (3,5-bis trifluoromethyl)-N-(3 -amino-4-methylphenyl)-)-benzamide;
condensing the compound of fonnula IV with aqueous cyanamide at reflux temperature in n-butanol solvent to obtain a compound of formula V, (3,5-bis- trifluoromethyl)-N-(3-guanidino - 4-methylphenyl)-benzamide;
condensing the compound of formiila (V) with 3-dimethylamino-l-pyridin-3-yl- propenone in presence of base at reflux temperature to obtain tiie compound of formula (I).
Dated this 28® day of February, 2009
^ / Dr. A.K.S.BHUJANGA RAO PRESroENT (TECHNICAL) NATCO PHARMA LIMITED NATCO RESEARCH CENTRE HYDERABAD
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 475-CHE-2009 FORM-18 09-11-2009.pdf | 2009-11-09 |
| 1 | 475-CHE-2009-AbandonedLetter.pdf | 2017-12-14 |
| 2 | Correspondence by Applicant_Examination report_24-10-2017.pdf | 2017-10-24 |
| 2 | 475-che-2009 form-3 21-06-2010.pdf | 2010-06-21 |
| 3 | Form3_After Filing_10-08-2017.pdf | 2017-08-10 |
| 3 | 475-che-2009 form-3 07-02-2011.pdf | 2011-02-07 |
| 4 | 475-CHE-2009-FER.pdf | 2017-05-24 |
| 4 | 475-che-2009 correspondence others 07-02-2011.pdf | 2011-02-07 |
| 5 | Form3_After Filing_09-01-2017.pdf | 2017-01-09 |
| 5 | 475-CHE-2009 FORM-3 08-03-2012.pdf | 2012-03-08 |
| 6 | 475-CHE-2009 CORRESPONDENCE OTHERS 10-04-2015.pdf | 2015-04-10 |
| 6 | 475-CHE-2009 CORRESPONDENCE OTHERS 08-03-2012.pdf | 2012-03-08 |
| 7 | 475-CHE-2009 FORM-3 10-04-2015.pdf | 2015-04-10 |
| 7 | 475-CHE-2009 FORM 5.pdf | 2012-06-13 |
| 8 | 475-CHE-2009 FORM 3.pdf | 2012-06-13 |
| 8 | 475-CHE-2009 ABSTRACT.pdf | 2012-06-13 |
| 9 | 475-CHE-2009 FORM 18.pdf | 2012-06-13 |
| 9 | 475-CHE-2009 CLAIMS.pdf | 2012-06-13 |
| 10 | 475-CHE-2009 CORRESPONDENCE OTHERS.pdf | 2012-06-13 |
| 10 | 475-CHE-2009 FORM 1.pdf | 2012-06-13 |
| 11 | 475-CHE-2009 DESCRIPTION (COMPLETE).pdf | 2012-06-13 |
| 11 | 475-CHE-2009 DRAWINGS.pdf | 2012-06-13 |
| 12 | 475-CHE-2009 DESCRIPTION (COMPLETE).pdf | 2012-06-13 |
| 12 | 475-CHE-2009 DRAWINGS.pdf | 2012-06-13 |
| 13 | 475-CHE-2009 CORRESPONDENCE OTHERS.pdf | 2012-06-13 |
| 13 | 475-CHE-2009 FORM 1.pdf | 2012-06-13 |
| 14 | 475-CHE-2009 CLAIMS.pdf | 2012-06-13 |
| 14 | 475-CHE-2009 FORM 18.pdf | 2012-06-13 |
| 15 | 475-CHE-2009 ABSTRACT.pdf | 2012-06-13 |
| 15 | 475-CHE-2009 FORM 3.pdf | 2012-06-13 |
| 16 | 475-CHE-2009 FORM 5.pdf | 2012-06-13 |
| 16 | 475-CHE-2009 FORM-3 10-04-2015.pdf | 2015-04-10 |
| 17 | 475-CHE-2009 CORRESPONDENCE OTHERS 08-03-2012.pdf | 2012-03-08 |
| 17 | 475-CHE-2009 CORRESPONDENCE OTHERS 10-04-2015.pdf | 2015-04-10 |
| 18 | 475-CHE-2009 FORM-3 08-03-2012.pdf | 2012-03-08 |
| 18 | Form3_After Filing_09-01-2017.pdf | 2017-01-09 |
| 19 | 475-CHE-2009-FER.pdf | 2017-05-24 |
| 19 | 475-che-2009 correspondence others 07-02-2011.pdf | 2011-02-07 |
| 20 | Form3_After Filing_10-08-2017.pdf | 2017-08-10 |
| 20 | 475-che-2009 form-3 07-02-2011.pdf | 2011-02-07 |
| 21 | Correspondence by Applicant_Examination report_24-10-2017.pdf | 2017-10-24 |
| 21 | 475-che-2009 form-3 21-06-2010.pdf | 2010-06-21 |
| 22 | 475-CHE-2009-AbandonedLetter.pdf | 2017-12-14 |
| 22 | 475-CHE-2009 FORM-18 09-11-2009.pdf | 2009-11-09 |
Search Strategy
| 1 | Searchstrategy_15-05-2017.pdf |